Timberlyne
1 known investors
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Timberlyne do?
- Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets. Its lead program, CM313, is a CD38-targeting monoclonal antibody being tested across conditions including immune thrombocytopenia, systemic lupus erythematosus, and multiple myeloma.
- Who are Timberlyne's investors?
- Timberlyne's investors include Bain Capital Life Sciences.